1. Home
  2. VRXA vs CMPX Comparison

VRXA vs CMPX Comparison

Compare VRXA & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veraxa Biotech AG Ordinary Shares

VRXA

Veraxa Biotech AG Ordinary Shares

N/A

Current Price

$1.76

Market Cap

390.3M

Sector

Health Care

ML Signal

N/A

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$1.91

Market Cap

408.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRXA
CMPX
Founded
N/A
2014
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.3M
408.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
VRXA
CMPX
Price
$1.76
$1.91
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$14.57
AVG Volume (30 Days)
951.5K
2.3M
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$934.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.70
$1.61
52 Week High
$4.50
$6.88

Technical Indicators

Market Signals
Indicator
VRXA
CMPX
Relative Strength Index (RSI) 29.98 34.71
Support Level $1.74 $1.88
Resistance Level $2.29 $2.02
Average True Range (ATR) 0.20 0.10
MACD 0.04 -0.02
Stochastic Oscillator 13.46 10.20

Price Performance

Historical Comparison
VRXA
CMPX

About VRXA Veraxa Biotech AG Ordinary Shares

Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: